# Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors

> **NCT07028008** · NA · NOT_YET_RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 9 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** tumor-infiltrating lymphocyte (TIL)

## Key facts

- **NCT ID:** NCT07028008
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2027-05-28
- **Final completion:** 2029-05-28
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028008, "Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07028008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*